Pediatric research · 2026
Proinflammatory monocyte-derived granulocyte-macrophage colony-stimulating factor fuels airway inflammation in bronchopulmonary dysplasia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang ShuShu, Wang Xuesong, Wang Dongyao, Fu Binqing, Chen Mingwu, Lv Yong, Wang Huiru, Zhou Haoquan, Zhou Yonggang, Wei Haiming
Аннотация
BACKGROUND: Bronchopulmonary dysplasia (BPD) remains a leading cause of morbidity and long-term respiratory complications in preterm neonates. Effective strategies for moderate-severe BPD are currently lacking.
METHODS: Tracheal aspirate (TA) samples were collected from 62 preterm neonates, and the immune cell composition was analyzed using multicolor flow cytometry. Subsequently, CD14+ monocytes were isolated and purified from the TA samples for transcriptomic sequencing analysis. Cytokine arrays and enzyme-linked immunosorbent assays were utilized in the cytokine level detection from TA samples. Finally, we evaluated the efficacy of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitor in alleviating lung inflammation resembling BPD in a neonatal rat model of hyperoxia lung injury.
RESULTS: CD14+monocytes in TA samples from patients with BPD were significantly increased, and exhibited a pro-inflammatory transcriptomic profile, producing large amount of GM-CSF in the airway. Upregulated toll-like receptor 9 (TLR9) expression in these monocytes was observed. Baricitinib, a JAK1/JAK2 inhibitor, effectively reduced lung inflammation induced by hyperoxia and GM-CSF in a neonate rat model mimicking BPD.
CONCLUSIONS: GM-CSF derived from airway pro-inflammatory monocytes exacerbated inflammation in preterm neonates with BPD, particularly in moderate-severe cases. Baricitinib emerges as a promising therapeutic option, offering new hope for mitigating the inflammatory burden associated with moderate-severe BPD.
IMPACT: Moderate-to-severe bronchopulmonary dysplasia in preterm infants is closely linked to the sustained production of high levels of GM-CSF (granulocyte-macrophage colony-stimulating factor) by airway inflammatory monocytes. We propose a local GM-CSF-driven inflammatory positive-feedback loop in airway of patients with BPD. Interrupting the downstream GM-CSF signaling pathway may hold promise as the next effective therapeutic strategy.
METHODS: Tracheal aspirate (TA) samples were collected from 62 preterm neonates, and the immune cell composition was analyzed using multicolor flow cytometry. Subsequently, CD14+ monocytes were isolated and purified from the TA samples for transcriptomic sequencing analysis. Cytokine arrays and enzyme-linked immunosorbent assays were utilized in the cytokine level detection from TA samples. Finally, we evaluated the efficacy of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitor in alleviating lung inflammation resembling BPD in a neonatal rat model of hyperoxia lung injury.
RESULTS: CD14+monocytes in TA samples from patients with BPD were significantly increased, and exhibited a pro-inflammatory transcriptomic profile, producing large amount of GM-CSF in the airway. Upregulated toll-like receptor 9 (TLR9) expression in these monocytes was observed. Baricitinib, a JAK1/JAK2 inhibitor, effectively reduced lung inflammation induced by hyperoxia and GM-CSF in a neonate rat model mimicking BPD.
CONCLUSIONS: GM-CSF derived from airway pro-inflammatory monocytes exacerbated inflammation in preterm neonates with BPD, particularly in moderate-severe cases. Baricitinib emerges as a promising therapeutic option, offering new hope for mitigating the inflammatory burden associated with moderate-severe BPD.
IMPACT: Moderate-to-severe bronchopulmonary dysplasia in preterm infants is closely linked to the sustained production of high levels of GM-CSF (granulocyte-macrophage colony-stimulating factor) by airway inflammatory monocytes. We propose a local GM-CSF-driven inflammatory positive-feedback loop in airway of patients with BPD. Interrupting the downstream GM-CSF signaling pathway may hold promise as the next effective therapeutic strategy.